FDA accepts Jazz Pharma’s application for JZP-258, action date July 21

Under Priority Review status, the FDA has accepted Jazz Pharmaceuticals’ (NASDAQ:JAZZ) marketing application for JZP-258 for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy. The agency’s action date is July 21.

JZP-258 is an oxybate compound like Xyrem (sodium oxybate) but with 92% less sodium.

Shares up 5% after hours.

https://seekingalpha.com/news/3555219-fda-accepts-jazz-pharmas-application-for-jzpminus-258-action-date-july-21